ReviewBiomarker research2026
Semaphorins: from CD8⁺ T cells to cancer immunotherapy.
Review in Biomarker research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Semaphorins were initially identified as axon guidance molecules in the nervous system, where they transmit repulsive signals to restrict axonal growth by regulating the dynamics of growth cone cytoskeletal structures. Subsequent studies have demonstrated that semaphorin signaling can restrict the migration of CD8⁺ T cell precursors driven by chemokines, thereby maintaining the corticomedullary structure of the thymus. In recent years, increasing evidence has revealed that semaphorins and their receptors (such as plexins and neuropilins) play critical roles in the lymph node homing and activation of CD8⁺ T cells, as well as in their migration and effector functions within the tumor microenvironment. This review summarizes recent advances in understanding the roles of semaphorins and their receptors in CD8⁺ T cell development, migration, and function, highlighting their potential as targets for cancer immunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.